These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Matrix metalloproteinase-1 expression in the circulation of patients with Kawasaki disease and its role in the pathogenesis of coronary artery lesions]. Yang SW; Wang DW; Li J; Qin YM; Wang FM; Cao LM; Zhang LF; Hu Z Zhonghua Er Ke Za Zhi; 2005 Aug; 43(8):612-5. PubMed ID: 16191276 [TBL] [Abstract][Full Text] [Related]
3. [Clinical value of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 for the prediction and early diagnosis of coronary artery lesion in patients with Kawasaki disease]. Peng Q; Zhou TF; Chen CH; Hua YM; Liu HM; Hong H; Zhang LY; Wu Q Zhonghua Er Ke Za Zhi; 2005 Sep; 43(9):676-80. PubMed ID: 16191301 [TBL] [Abstract][Full Text] [Related]
4. The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases. Senzaki H Arch Dis Child; 2006 Oct; 91(10):847-51. PubMed ID: 16990356 [TBL] [Abstract][Full Text] [Related]
5. Elastolytic matrix metalloproteinases and coronary outcome in children with Kawasaki disease. Lau AC; Rosenberg H; Duong TT; McCrindle BW; Yeung RS Pediatr Res; 2007 Jun; 61(6):710-5. PubMed ID: 17426658 [TBL] [Abstract][Full Text] [Related]
6. Relationships between matrix metalloproteinases and tissue inhibitor of metalloproteinases in the wall of abdominal aortic aneurysms. Nishimura K; Ikebuchi M; Kanaoka Y; Ohgi S; Ueta E; Nanba E; Ito H Int Angiol; 2003 Sep; 22(3):229-38. PubMed ID: 14612849 [TBL] [Abstract][Full Text] [Related]
7. Expression of membrane-type 1 matrix metalloproteinase in coronary vessels of allotransplanted primate hearts. Tsukioka K; Suzuki J; Kawauchi M; Wada Y; Zhang T; Nishio A; Koide N; Endoh M; Takayama K; Takamoto S; Isobe M; Amano J J Heart Lung Transplant; 2000 Dec; 19(12):1193-8. PubMed ID: 11124489 [TBL] [Abstract][Full Text] [Related]
9. Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease. Chua PK; Melish ME; Yu Q; Yanagihara R; Yamamoto KS; Nerurkar VR Clin Diagn Lab Immunol; 2003 Mar; 10(2):308-14. PubMed ID: 12626459 [TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase 9 activity leads to elastin breakdown in an animal model of Kawasaki disease. Lau AC; Duong TT; Ito S; Yeung RS Arthritis Rheum; 2008 Mar; 58(3):854-63. PubMed ID: 18311803 [TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase-9 in vascular lesions and endothelial regulation in Kawasaki disease. Sakata K; Hamaoka K; Ozawa S; Niboshi A; Yahata T; Fujii M; Hamaoka A; Toiyama K; Nishida M; Itoi T Circ J; 2010 Aug; 74(8):1670-5. PubMed ID: 20534943 [TBL] [Abstract][Full Text] [Related]
12. Cell distribution differences of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in patients with Kawasaki disease. Korematsu S; Ohta Y; Tamai N; Takeguchi M; Goto C; Miyahara H; Kawano T; Izumi T Pediatr Infect Dis J; 2012 Sep; 31(9):973-4. PubMed ID: 22895216 [TBL] [Abstract][Full Text] [Related]
13. [Roles of matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase and hs-CRP in Kawasaki disease]. Chen R; Zhang AR; Zhao XX; Li ZH Zhongguo Dang Dai Er Ke Za Zhi; 2009 Dec; 11(12):989-91. PubMed ID: 20113606 [TBL] [Abstract][Full Text] [Related]
14. The distribution of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the lungs of congenital diaphragmatic hernia patients and age-matched controls. Masumoto K; de Rooij JD; Suita S; Rottier R; Tibboel D; de Krijger RR Histopathology; 2006 Apr; 48(5):588-95. PubMed ID: 16623785 [TBL] [Abstract][Full Text] [Related]
15. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. Allaire E; Forough R; Clowes M; Starcher B; Clowes AW J Clin Invest; 1998 Oct; 102(7):1413-20. PubMed ID: 9769334 [TBL] [Abstract][Full Text] [Related]
16. Relevance of tenascin-C and matrix metalloproteinases in vascular abnormalities in murine hypoplastic lungs. Chinoy MR; Miller SA Biol Neonate; 2006; 90(3):185-96. PubMed ID: 16699260 [TBL] [Abstract][Full Text] [Related]
17. [Expression of matrix metalloproteinase-2, 9 and it's tissue inhibitor-1, 2 in endometrial carcinoma]. Guo W; Chen G; Zhu C; Wang H Zhonghua Fu Chan Ke Za Zhi; 2002 Oct; 37(10):604-7. PubMed ID: 12487935 [TBL] [Abstract][Full Text] [Related]
18. Temporal expression of extracellular matrix metalloproteinases and tissue plasminogen activator in the development of collateral vessels in the canine model of coronary occlusion. Tyagi SC; Kumar S; Cassatt S; Parker JL Can J Physiol Pharmacol; 1996 Aug; 74(8):983-95. PubMed ID: 8960389 [TBL] [Abstract][Full Text] [Related]
19. Pressure distention compared with pharmacologic relaxation in vein grafting upregulates matrix metalloproteinase-2 and -9. Chung AW; Rauniyar P; Luo H; Hsiang YN; van Breemen C; Okon EB J Vasc Surg; 2005 Oct; 42(4):747-56. PubMed ID: 16242564 [TBL] [Abstract][Full Text] [Related]
20. Altered balance between extracellular proteolysis and antiproteolysis is associated with adaptive coronary arteriogenesis. Cai W; Vosschulte R; Afsah-Hedjri A; Koltai S; Kocsis E; Scholz D; Kostin S; Schaper W; Schaper J J Mol Cell Cardiol; 2000 Jun; 32(6):997-1011. PubMed ID: 10888253 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]